Literature DB >> 2137997

Effects of age on plasma protein binding of sufentanil.

C Meistelman1, D Benhamou, J Barre, J C Levron, V Mahe, X Mazoit, C Ecoffey.   

Abstract

The plasma protein binding of sufentanil has been studied in newborns, infants (0.5 +/- 0.3 yr), children (6.8 +/- 3.0 yr), and adults (39.5 +/- 9.0 yr). Binding of sufentanil was determined in vitro by equilibrium dialysis, and radioactive tritiated sufentanil was used for the determination of drug concentrations in plasma and buffer. The free fraction of sufentanil was significantly higher in the newborn (19.5 +/- 2.7%; P less than 0.01) than in the other age groups. The free fraction was also significantly higher in infants (11.5 +/- 3.2%; P less than 0.01) than in children (8.1 +/- 1.4%) or in adults (7.8 +/- 1.5%) but did not differ significantly between children and adults. The free fraction of sufentanil was strongly correlated with the alpha 1-acid glycoprotein plasma concentration (r = -0.73; P less than 0.001) whereas it was weakly correlated with albumin plasma concentration (r = -0.35; P less than 0.05). These data suggest that the lower concentration of alpha 1-acid glycoprotein in newborns and infants probably accounts for the decrease in protein binding of sufentanil in these age groups when compared with that in older children or adults. The increased free fraction in the neonate might contribute to the enhanced effects of lipophilic opioids in the neonate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137997     DOI: 10.1097/00000542-199003000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  17 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

8.  Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.

Authors:  Pankaj K Sethi; Catherine A White; Brian S Cummings; Ronald N Hines; Srinivasa Muralidhara; James V Bruckner
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

Review 9.  Adverse effects of regional anaesthesia in children.

Authors:  B J Dalens; J X Mazoit
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

10.  [Analgesia with opioids in the paediatric patient.].

Authors:  C Schlünder
Journal:  Schmerz       Date:  1992-12       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.